Tenofovir disoproxil Zentiva 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
IB/0029 
C.I.2.a - Change in the SPC, Labelling or PL of a 
03/07/2023 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
IB/0028 
C.I.2.a - Change in the SPC, Labelling or PL of a 
15/09/2022 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
SmPC and 
Annex II 
IA/0027 
A.4 - Administrative change - Change in the name 
09/06/2022 
n/a 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
N/0026 
Minor change in labelling or package leaflet not 
17/03/2022 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0025 
B.II.e.2.z - Change in the specification parameters 
23/11/2021 
n/a 
and/or limits of the immediate packaging of the 
finished product - Other variation 
IB/0024/G 
This was an application for a group of variations. 
20/10/2021 
n/a 
B.II.e.2.z - Change in the specification parameters 
and/or limits of the immediate packaging of the 
finished product - Other variation 
B.II.e.2.a - Change in the specification parameters 
and/or limits of the immediate packaging of the 
finished product - Tightening of specification limits 
R/0023 
Renewal of the marketing authorisation. 
20/05/2021 
16/07/2021 
Annex II and 
Page 2/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0022 
C.I.2.a - Change in the SPC, Labelling or PL of a 
28/01/2021 
16/07/2021 
SmPC, Annex 
Labelling 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
II, Labelling 
and PL 
PSUSA/2892/
Periodic Safety Update EU Single assessment - 
12/11/2020 
14/01/2021 
SmPC, Annex 
Refer to Scientific conclusions and grounds recommending 
202003 
tenofovir disoproxil 
II, Labelling 
the variation to terms of the Marketing Authorisation(s)’ for 
and PL 
PSUSA/2892/202003. 
PSUSA/2892/
Periodic Safety Update EU Single assessment - 
14/11/2019 
13/01/2020 
SmPC 
Refer to Scientific conclusions and grounds recommending 
201903 
tenofovir disoproxil 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/2892/201903. 
IB/0020 
C.I.2.a - Change in the SPC, Labelling or PL of a 
29/08/2019 
16/09/2019 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0017/G 
This was an application for a group of variations. 
06/07/2019 
n/a 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
B.I.a.2.e - Changes in the manufacturing process of 
the AS - Minor change to the restricted part of an 
Page 3/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ASMF 
IB/0018/G 
This was an application for a group of variations. 
23/05/2019 
16/09/2019 
SmPC, Annex 
II and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.11.z - Introduction of, or change(s) to, the 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
IA/0016 
B.I.b.2.a - Change in test procedure for AS or 
29/04/2019 
n/a 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
IAIN/0015 
B.I.a.1.a - Change in the manufacturer of AS or of a 
12/03/2019 
n/a 
starting material/reagent/intermediate for AS - The 
proposed manufacturer is part of the same 
pharmaceutical group as the currently approved 
manufacturer 
IB/0014/G 
This was an application for a group of variations. 
19/02/2019 
16/09/2019 
SmPC and PL 
C.I.z - Changes (Safety/Efficacy) of Human and 
Veterinary Medicinal Products - Other variation 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
Page 4/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0013 
C.I.11.z - Introduction of, or change(s) to, the 
07/02/2019 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
IG/1029 
A.5.b - Administrative change - Change in the name 
18/12/2018 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
PSUSA/2892/
Periodic Safety Update EU Single assessment - 
31/10/2018 
n/a 
PRAC Recommendation - maintenance 
201803 
tenofovir disoproxil 
IA/0011 
B.I.a.3.a - Change in batch size (including batch size 
13/09/2018 
n/a 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
IB/0009 
C.I.11.z - Introduction of, or change(s) to, the 
03/09/2018 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
IAIN/0008/G 
This was an application for a group of variations. 
18/05/2018 
07/12/2018 
Annex II and 
PL 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.a - Replacement or addition of a 
Page 5/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
IB/0007/G 
This was an application for a group of variations. 
18/01/2018 
07/12/2018 
SmPC and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
PSUSA/2892/
Periodic Safety Update EU Single assessment - 
26/10/2017 
n/a 
PRAC Recommendation - maintenance 
201703 
tenofovir disoproxil 
Page 6/7 
 
 
 
 
 
 
 
 
 
 
II/0001 
B.I.z - Update of Tenofovir disoproxil phosphate DMF 
27/04/2017 
n/a 
no. EU/ASMF/00052 with the addition of a new 
intermediate active substance manufacturer. 
B.I.z - Quality change - Active substance - Other 
variation 
IB/0004 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
20/04/2017 
18/01/2018 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
IB/0003 
B.II.e.5.z - Change in pack size of the finished 
24/02/2017 
18/01/2018 
SmPC, 
product - Other variation 
Labelling and 
PL 
IB/0002/G 
This was an application for a group of variations. 
27/01/2017 
18/01/2018 
SmPC, 
Labelling and 
PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Page 7/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
